Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca

Keywords

Psoriases ×

Mostra di più Keywords

Sommario

Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

34 Risultati di ricerca.

44967_dbGaP phs000019 Collaborative Association Study of Psoriasis - pht000063.v1.p1

- 03/06/22 - 5 moduli, 1 ItemGroup, 18 elementi, 1 linguaggio

ItemGroup: pht000063

Principal Investigator: Gonçalo R. Abecasis, University of Michigan School of Public Health, Ann Arbor, MI, USA MeSH: Psoriasis,Psoriatic Arthritis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000019 The goal of this collaborative study is to combine the resources and expertise of three groups with long-standing studies of psoriasis genetics in order to identify new genetic susceptibility factors for psoriasis, a common inflammatory skin disease that affects over 4 million Americans. *Consent groups and participant set* - General research use (GRU): 1677 (950 cases, 692 controls, 35 others) - Autoimmune disease (AD): 1198 (449 cases, 734 controls, 15 others)

pht000064.v1.p1

1 ItemGroup 4 elementi

pht000179.v1.p1

1 ItemGroup 3 elementi

pht000180.v1.p1

1 ItemGroup 7 elementi

Screening Visit 1 Psoriasis NCT02695940

- 27/09/21 - 1 modulo, 10 itemgroups, 62 elementi, 1 linguaggio

Itemgroups: Administrative data,Eligibility criteria,Demography,Medical History,Treated body regions,Vital signs,ECG,Blood sample,Urine sample,miscellaneous

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Eligibility NCT00408187 Psoriasis - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 30 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00408187

Eligibility NCT00606450 Psoriasis - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 24 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00606450

Eligibility NCT01194219 Plaque Psoriasis - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 29 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT01194219

Eligibility NCT00329303 Psoriasis - Eligibility

- 17/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00329303

Eligibility NCT00245765 Chronic Plaque Psoriasis - Eligibility

- 17/09/21 - 1 modulo, 2 itemgroups, 12 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00245765

Eligibility NCT00852670 Plaque Psoriasis - Eligibility

- 17/09/21 - 1 modulo, 2 itemgroups, 7 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00852670

Eligibility NCT00574249 Chronic Plaque Psoriasis - Eligibility

- 17/09/21 - 1 modulo, 2 itemgroups, 11 elementi, 2 lingue

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00574249

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

- 15/06/21 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria,Exclusion Criteria

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

PASI Psoriasis MIPSO EudraCT 2014-003022-40

- 11/06/18 - 1 modulo, 2 itemgroups, 33 elementi, 1 linguaggio

Itemgroups: Use of the form,Psoriasis Area and Severity Index

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger PASI: Fredriksson T, Pettersson U: Severe psoria - sis – Oral therapy with a new retinoid. Dermatologica 178; 157: 238–244.

Visit 6 Psoriasis NCT02695940

- 22/01/18 - 1 modulo, 8 itemgroups, 50 elementi, 1 linguaggio

Itemgroups: Administrative data,Medical History and physical exam,Vital signs,ECG,Blood sample,Urine sample,Picture,Signature

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.